Medicenna Therapeutics Corp.

We apologize for the inconvenience, this event has been cancelled. Please check back for further updates.
Financial Advisors, Investment Advisors, Analysts, and Institutional Portfolio Managers are cordially invited to attend a presentation for: Corporate Presentation In Philadelphia
Feb 21, 2018 - 12:00 PM EST
Davio's Northern Italian Steakhouse (Chairman's Room) - 111 South 17th Street, Philadelphia, Pennsylvania

Medicenna is a clinical stage immuno-oncology company developing novel highly selective versions of IL-2, IL-4 and IL-13 Superkines™ and first in class Empowered Cytokines™ (ECs). Its wholly owned subsidiary, Houston-based Medicenna BioPharma, is specifically targeting the Interleukin-4 Receptor (IL4R), which is over-expressed by at least 20 different types of cancer affecting more than one million new cancer patients every year. Medicenna's lead IL4-EC, MDNA55 is enrolling patients in a Phase 2b clinical trial for rGBM at leading brain cancer centres in the US. MDNA55 has completed 3 clinical trials in 72 patients, including 66 adults with rGBM, demonstrated compelling efficacy and obtained Fast-Track and Orphan Drug status from USFDA. Unlike most other cancer therapies, Medicenna's IL4- ECs have the potential to purge both the tumor and the immunosuppressive tumor microenvironment, offering a unique treatment paradigm for a large majority of cancer patients.